Disease · MONDO_0004995
Comparisons in its trials71
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 71
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause | 22,208 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| Aims 1, 2B, and 3 Groups vs Aim 2A Group: serious adverse events | 40,642 of 386,276 | 0 of 25 | 386,301 | NCT05214573 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 50 of 2,220 | 63 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions | 88 of 2,220 | 96 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions | 68 of 2,220 | 60 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions | 186 of 2,220 | 191 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG vs Combined MET/SU: Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions | 181 of 2,220 | 188 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events | 321 of 2,220 | 323 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 72 of 2,220 | 62 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause | 139 of 2,220 | 160 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
Combined RSG: Main Study and Observational Follow-up vs Combined MET/SU: Main Study and Observational Follow-up: Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined | 0 of 2,220 | 0 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Combined RSG vs Combined MET/SU: Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions | 53 of 2,220 | 64 of 2,227 | 4,447 | NCT00379769 | Trial comparisons |
| Cycloset vs Placebo: Subjects Experiencing Serious Adverse Events | 176 of 2,054 | 98 of 1,016 | 3,070 | NCT00377676 | Trial comparisons |
| Cycloset vs Placebo: serious adverse events | 176 of 2,054 | 98 of 1,016 | 3,070 | NCT00377676 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 212 of 983 | 204 of 990 | 1,973 | NCT02207634 | Trial comparisons |
| Dapagliflozin vs Placebo: serious adverse events | 41 of 482 | 46 of 483 | 965 | NCT01042977 | Trial comparisons |
| Experimental vs Placebo Comparator: serious adverse events | 27 of 460 | 26 of 462 | 922 | NCT01031680 | Trial comparisons |
| Varenicline (Var) vs Placebo (Pbo): Number of Responders With Continuous Abstinence (CA) Through Week 24 | 100 of 353 | 34 of 350 | 703 | NCT00282984 | Trial comparisons |
| Varenicline (Var) vs Placebo (Pbo): Number of Participants With a 4 Week Point Prevalence of Smoking Cessation | 99 of 353 | 57 of 350 | 703 | NCT00282984 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004995/comparisons